stockrowSarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024.
- Revenue
- −4.51%
- EPS
- +46.0%
- Free cash flow
- +231.8%
- Total debt
- −17.2%
Quarter to September 2026, against a year earlier
Follow SRPT
Alert me
Sarepta Therapeutics, Inc. (SRPT) Return on assets
Sarepta Therapeutics, Inc.'s return on assets over the twelve months to 30 September 2026 was −3.44%, up 16.1 percentage points from fiscal 2025 (−19.5%). Over the past ten years it has ranged from −77.4% (fiscal 2015) to 6.51% (fiscal 2024); the current reading is higher than 64% of that period. That is above the Biotechnology industry median of −46.1% and above the Healthcare sector median of −29.5%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −19.5% | (26.02) |
| FY2024 | 6.51% | 23.28 |
| FY2023 | −16.8% | 5.65 |
| FY2022 | −22.4% | (8.76) |
| FY2021 | −13.7% | 9.39 |
| FY2020 | −23.1% | 18.23 |
| FY2019 | −41.3% | (16.74) |
| FY2018 | −24.5% | (18.69) |
| FY2017 | −5.85% | 70.74 |
| FY2016 | −76.6% | 0.77 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. compare | 13.3% |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.00% |
| MESO Mesoblast Limited compare | 0.00% |
| SRPT Sarepta Therapeutics, Inc. | −3.44% |
| MRVI Maravai LifeSciences Holdings, Inc. compare | −9.06% |
| VIR Vir Biotechnology, Inc. compare | −17.3% |
| TRVI Trevi Therapeutics, Inc. compare | −19.0% |
| MAZE Maze Therapeutics, Inc. compare | −32.0% |
| REPL Replimune Group, Inc. compare | −71.0% |
| Biotechnology industry median | −46.1% |
| Healthcare sector median | −29.5% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)